Zentalis Pharmaceuticals’ (ZNTL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report issued on Monday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Several other analysts have also recently issued reports on the company. Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. UBS Group dropped their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $1.79 on Monday. The stock’s 50 day simple moving average is $2.14 and its two-hundred day simple moving average is $2.92. Zentalis Pharmaceuticals has a 1 year low of $1.61 and a 1 year high of $16.27. The company has a market cap of $127.56 million, a PE ratio of -0.72 and a beta of 1.75.

Insiders Place Their Bets

In related news, insider Ingmar Bruns purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, February 6th. The stock was acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the transaction, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jan Skvarka acquired 60,000 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Corton Capital Inc. bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at approximately $32,000. Captrust Financial Advisors bought a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $33,000. Erste Asset Management GmbH bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Paloma Partners Management Co bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $37,000. Finally, Prudential Financial Inc. bought a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at $39,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.